
<div id="jpedal" style="overflow: hidden; position: relative; width: 909px; height: 1212px;">
<style type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position:absolute;
	white-space:nowrap;
	overflow:visible;
}
</style>
<style type="text/css" >

#t1_4{left:55px;top:86px;word-spacing:-1px;}
#t2_4{left:278px;top:84px;}
#t3_4{left:288px;top:84px;}
#t4_4{left:297px;top:86px;word-spacing:0.8px;}
#t5_4{left:55px;top:101px;word-spacing:4.7px;}
#t6_4{left:69px;top:116px;word-spacing:2.2px;}
#t7_4{left:55px;top:132px;word-spacing:29.1px;}
#t8_4{left:55px;top:147px;word-spacing:12.6px;}
#t9_4{left:55px;top:162px;word-spacing:4.6px;}
#ta_4{left:55px;top:205px;}
#tb_4{left:55px;top:223px;word-spacing:0.8px;}
#tc_4{left:55px;top:238px;word-spacing:19.1px;}
#td_4{left:55px;top:253px;word-spacing:11.7px;}
#te_4{left:55px;top:269px;word-spacing:10px;}
#tf_4{left:55px;top:284px;word-spacing:3.1px;}
#tg_4{left:55px;top:299px;word-spacing:9.1px;}
#th_4{left:55px;top:314px;word-spacing:10.3px;}
#ti_4{left:55px;top:330px;word-spacing:1.2px;}
#tj_4{left:55px;top:345px;word-spacing:2.1px;}
#tk_4{left:55px;top:360px;word-spacing:11.7px;}
#tl_4{left:55px;top:375px;word-spacing:25.4px;}
#tm_4{left:55px;top:390px;word-spacing:6.3px;}
#tn_4{left:55px;top:406px;word-spacing:2.2px;}
#to_4{left:216px;top:404px;}
#tp_4{left:247px;top:406px;word-spacing:2.2px;}
#tq_4{left:55px;top:421px;word-spacing:4.6px;}
#tr_4{left:266px;top:419px;}
#ts_4{left:69px;top:436px;word-spacing:10.9px;}
#tt_4{left:55px;top:451px;word-spacing:1.2px;}
#tu_4{left:55px;top:466px;word-spacing:-0.7px;}
#tv_4{left:55px;top:482px;word-spacing:22.5px;}
#tw_4{left:55px;top:497px;word-spacing:3.1px;}
#tx_4{left:55px;top:512px;word-spacing:22.5px;}
#ty_4{left:390px;top:511px;}
#tz_4{left:410px;top:512px;}
#t10_4{left:55px;top:527px;word-spacing:20.8px;}
#t11_4{left:55px;top:543px;word-spacing:18.8px;}
#t12_4{left:55px;top:558px;word-spacing:-0.3px;}
#t13_4{left:202px;top:556px;}
#t14_4{left:228px;top:558px;word-spacing:-0.2px;}
#t15_4{left:55px;top:573px;word-spacing:10.2px;}
#t16_4{left:55px;top:588px;word-spacing:2.3px;}
#t17_4{left:342px;top:587px;}
#t18_4{left:357px;top:588px;word-spacing:2.3px;}
#t19_4{left:55px;top:604px;word-spacing:17.1px;}
#t1a_4{left:55px;top:619px;word-spacing:-0.7px;}
#t1b_4{left:156px;top:617px;}
#t1c_4{left:182px;top:619px;word-spacing:-0.7px;}
#t1d_4{left:55px;top:634px;word-spacing:9.8px;}
#t1e_4{left:55px;top:649px;word-spacing:6.5px;}
#t1f_4{left:170px;top:648px;}
#t1g_4{left:186px;top:649px;word-spacing:6.6px;}
#t1h_4{left:55px;top:664px;word-spacing:3.6px;}
#t1i_4{left:55px;top:680px;word-spacing:3.1px;}
#t1j_4{left:161px;top:678px;}
#t1k_4{left:176px;top:680px;word-spacing:3.1px;}
#t1l_4{left:55px;top:695px;word-spacing:21.1px;}
#t1m_4{left:55px;top:710px;}
#t1n_4{left:110px;top:709px;}
#t1o_4{left:140px;top:710px;word-spacing:17.2px;}
#t1p_4{left:55px;top:725px;word-spacing:10.6px;}
#t1q_4{left:55px;top:741px;word-spacing:6.7px;}
#t1r_4{left:55px;top:756px;word-spacing:4.6px;}
#t1s_4{left:69px;top:771px;word-spacing:0.8px;}
#t1t_4{left:55px;top:786px;word-spacing:22.9px;}
#t1u_4{left:55px;top:801px;word-spacing:4px;}
#t1v_4{left:55px;top:817px;word-spacing:26.2px;}
#t1w_4{left:55px;top:832px;word-spacing:4.8px;}
#t1x_4{left:55px;top:847px;word-spacing:5.9px;}
#t1y_4{left:55px;top:862px;word-spacing:4.3px;}
#t1z_4{left:208px;top:861px;}
#t20_4{left:223px;top:862px;word-spacing:4.4px;}
#t21_4{left:55px;top:877px;word-spacing:5px;}
#t22_4{left:55px;top:893px;word-spacing:8px;}
#t23_4{left:55px;top:908px;word-spacing:11.5px;}
#t24_4{left:55px;top:923px;word-spacing:14.1px;}
#t25_4{left:55px;top:938px;word-spacing:8px;}
#t26_4{left:55px;top:954px;word-spacing:20.5px;}
#t27_4{left:55px;top:969px;word-spacing:-0.7px;}
#t28_4{left:55px;top:984px;word-spacing:13.1px;}
#t29_4{left:55px;top:999px;word-spacing:4.6px;}
#t2a_4{left:69px;top:1014px;word-spacing:17.2px;}
#t2b_4{left:55px;top:1030px;word-spacing:5.8px;}
#t2c_4{left:55px;top:1045px;word-spacing:21.2px;}
#t2d_4{left:55px;top:1060px;word-spacing:5.8px;}
#t2e_4{left:55px;top:1075px;word-spacing:2.8px;}
#t2f_4{left:324px;top:1074px;letter-spacing:0.1px;}
#t2g_4{left:355px;top:1075px;word-spacing:2.7px;}
#t2h_4{left:55px;top:1091px;word-spacing:12.2px;}
#t2i_4{left:55px;top:1106px;word-spacing:30px;}
#t2j_4{left:461px;top:86px;word-spacing:7.3px;}
#t2k_4{left:793px;top:84px;}
#t2l_4{left:803px;top:84px;}
#t2m_4{left:814px;top:86px;}
#t2n_4{left:461px;top:101px;word-spacing:1.6px;}
#t2o_4{left:744px;top:100px;}
#t2p_4{left:753px;top:100px;}
#t2q_4{left:763px;top:101px;word-spacing:3.8px;}
#t2r_4{left:461px;top:116px;word-spacing:2.7px;}
#t2s_4{left:570px;top:115px;}
#t2t_4{left:580px;top:115px;}
#t2u_4{left:591px;top:116px;word-spacing:10.2px;}
#t2v_4{left:461px;top:132px;word-spacing:1.7px;}
#t2w_4{left:461px;top:147px;word-spacing:12.3px;}
#t2x_4{left:461px;top:162px;word-spacing:2.7px;}
#t2y_4{left:461px;top:177px;word-spacing:8.8px;}
#t2z_4{left:461px;top:193px;word-spacing:11.1px;}
#t30_4{left:461px;top:208px;word-spacing:3.9px;}
#t31_4{left:507px;top:206px;}
#t32_4{left:522px;top:208px;word-spacing:4.2px;}
#t33_4{left:461px;top:223px;word-spacing:5.4px;}
#t34_4{left:461px;top:238px;word-spacing:15.7px;}
#t35_4{left:461px;top:253px;word-spacing:21.3px;}
#t36_4{left:461px;top:269px;word-spacing:2.4px;}
#t37_4{left:461px;top:284px;word-spacing:4.6px;}
#t38_4{left:475px;top:299px;word-spacing:9.8px;}
#t39_4{left:461px;top:314px;word-spacing:7.4px;}
#t3a_4{left:461px;top:330px;word-spacing:9.9px;}
#t3b_4{left:461px;top:345px;word-spacing:3.3px;}
#t3c_4{left:698px;top:343px;}
#t3d_4{left:708px;top:343px;}
#t3e_4{left:713px;top:345px;word-spacing:6.4px;}
#t3f_4{left:461px;top:360px;word-spacing:12.7px;}
#t3g_4{left:627px;top:358px;}
#t3h_4{left:636px;top:358px;}
#t3i_4{left:642px;top:360px;word-spacing:24.1px;}
#t3j_4{left:461px;top:375px;word-spacing:14px;}
#t3k_4{left:539px;top:375px;}
#t3l_4{left:553px;top:375px;word-spacing:-4.5px;}
#t3m_4{left:605px;top:374px;}
#t3n_4{left:615px;top:374px;}
#t3o_4{left:620px;top:375px;}
#t3p_4{left:623px;top:374px;}
#t3q_4{left:640px;top:375px;word-spacing:14.1px;}
#t3r_4{left:461px;top:390px;word-spacing:5px;}
#t3s_4{left:461px;top:406px;word-spacing:5.8px;}
#t3t_4{left:825px;top:404px;}
#t3u_4{left:835px;top:404px;}
#t3v_4{left:461px;top:421px;word-spacing:27.7px;}
#t3w_4{left:461px;top:436px;}
#t3x_4{left:475px;top:436px;word-spacing:-4.5px;}
#t3y_4{left:528px;top:435px;}
#t3z_4{left:537px;top:435px;}
#t40_4{left:542px;top:436px;word-spacing:9.9px;}
#t41_4{left:461px;top:451px;word-spacing:-0.2px;}
#t42_4{left:461px;top:466px;word-spacing:4.6px;}
#t43_4{left:475px;top:482px;word-spacing:1.7px;}
#t44_4{left:461px;top:497px;word-spacing:1.3px;}
#t45_4{left:461px;top:512px;word-spacing:1.7px;}
#t46_4{left:689px;top:511px;}
#t47_4{left:703px;top:512px;word-spacing:1.6px;}
#t48_4{left:461px;top:527px;word-spacing:-0.5px;}
#t49_4{left:461px;top:543px;word-spacing:22.3px;}
#t4a_4{left:461px;top:558px;word-spacing:0.4px;}
#t4b_4{left:461px;top:573px;word-spacing:4.6px;}
#t4c_4{left:475px;top:588px;word-spacing:5.2px;}
#t4d_4{left:461px;top:604px;word-spacing:6.3px;}
#t4e_4{left:461px;top:619px;}
#t4f_4{left:471px;top:617px;}
#t4g_4{left:491px;top:619px;word-spacing:24.1px;}
#t4h_4{left:461px;top:634px;word-spacing:11.8px;}
#t4i_4{left:461px;top:649px;word-spacing:17.3px;}
#t4j_4{left:690px;top:648px;}
#t4k_4{left:708px;top:649px;word-spacing:17.3px;}
#t4l_4{left:461px;top:664px;word-spacing:14.8px;}
#t4m_4{left:461px;top:680px;word-spacing:29.2px;}
#t4n_4{left:461px;top:695px;word-spacing:7.8px;}
#t4o_4{left:461px;top:710px;word-spacing:22.2px;}
#t4p_4{left:461px;top:725px;}
#t4q_4{left:508px;top:724px;}
#t4r_4{left:523px;top:725px;word-spacing:5.9px;}
#t4s_4{left:461px;top:740px;word-spacing:11.1px;}
#t4t_4{left:461px;top:756px;word-spacing:11.5px;}
#t4u_4{left:461px;top:771px;word-spacing:4.1px;}
#t4v_4{left:461px;top:786px;word-spacing:4.6px;}
#t4w_4{left:475px;top:801px;word-spacing:2.3px;}
#t4x_4{left:461px;top:817px;word-spacing:14.5px;}
#t4y_4{left:461px;top:832px;word-spacing:3.2px;}
#t4z_4{left:461px;top:847px;word-spacing:14.7px;}
#t50_4{left:461px;top:862px;word-spacing:11.6px;}
#t51_4{left:461px;top:877px;word-spacing:6.4px;}
#t52_4{left:461px;top:893px;word-spacing:6.4px;}
#t53_4{left:461px;top:908px;word-spacing:5px;}
#t54_4{left:461px;top:923px;word-spacing:8.9px;}
#t55_4{left:461px;top:938px;word-spacing:15.3px;}
#t56_4{left:461px;top:954px;word-spacing:10.1px;}
#t57_4{left:739px;top:952px;}
#t58_4{left:756px;top:954px;word-spacing:10px;}
#t59_4{left:461px;top:969px;word-spacing:22.9px;}
#t5a_4{left:461px;top:984px;word-spacing:15.4px;}
#t5b_4{left:461px;top:999px;word-spacing:17.6px;}
#t5c_4{left:461px;top:1014px;word-spacing:4.6px;}
#t5d_4{left:475px;top:1030px;word-spacing:6.1px;}
#t5e_4{left:461px;top:1045px;word-spacing:-0.1px;}
#t5f_4{left:461px;top:1060px;word-spacing:20.4px;}
#t5g_4{left:461px;top:1075px;word-spacing:19.1px;}
#t5h_4{left:461px;top:1091px;word-spacing:18.4px;}
#t5i_4{left:461px;top:1106px;word-spacing:18.5px;}
#t5j_4{left:461px;top:34px;word-spacing:3.9px;}
#t5k_4{left:461px;top:49px;word-spacing:4px;}
#t5l_4{left:536px;top:49px;word-spacing:3.9px;}
#t5m_4{left:858px;top:69px;}
#t5n_4{left:55px;top:1147px;}
#t5o_4{left:67px;top:1147px;word-spacing:3.7px;}
#t5p_4{left:534px;top:1147px;word-spacing:2.8px;}

.s4_4{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGI-AdvOT3b30f6db-B4;
	color: rgb(35,31,32);
}

.s9_4{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCOAH-AdvTA424;
	color: rgb(35,31,32);
}

.s5_4{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGK-AdvPi14;
	color: rgb(35,31,32);
}

.s7_4{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCNGH-AdvOT65f8a23b-I4;
	color: rgb(35,31,32);
}

.s6_4{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae814;
	color: rgb(35,31,32);
}

.s2_4{
	FONT-SIZE: 36.5px;
	FONT-FAMILY: JBCNGG-AdvP4C4E744;
	color: rgb(35,31,32);
}

.s8_4{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCPDD-AdvOT7d2ebc014;
	color: rgb(35,31,32);
}

.s3_4{
	FONT-SIZE: 36.5px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae814;
	color: rgb(35,31,32);
}

.s1_4{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae814;
	color: rgb(35,31,32);
}

.v1_4{
	-webkit-transform: scale(0.281, 0.25);
	-ms-transform: scale(0.281, 0.25);
	-moz-transform: scale(0.281, 0.25);
	-o-transform: scale(0.281, 0.25);
}

#form4_1{	border-style:none;	z-index:2;	position: absolute;	left:471px;	top:614px;	width:11px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_2{	border-style:none;	z-index:2;	position: absolute;	left:342px;	top:584px;	width:11px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_3{	border-style:none;	z-index:2;	position: absolute;	left:390px;	top:507px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_4{	border-style:none;	z-index:2;	position: absolute;	left:689px;	top:645px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_5{	border-style:none;	z-index:2;	position: absolute;	left:506px;	top:203px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_6{	border-style:none;	z-index:2;	position: absolute;	left:170px;	top:645px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_7{	border-style:none;	z-index:2;	position: absolute;	left:738px;	top:949px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_8{	border-style:none;	z-index:2;	position: absolute;	left:161px;	top:675px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_9{	border-style:none;	z-index:2;	position: absolute;	left:208px;	top:857px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_10{	border-style:none;	z-index:2;	position: absolute;	left:507px;	top:721px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_11{	border-style:none;	z-index:2;	position: absolute;	left:688px;	top:507px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_12{	border-style:none;	z-index:2;	position: absolute;	left:622px;	top:371px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_13{	border-style:none;	z-index:2;	position: absolute;	left:266px;	top:417px;	width:22px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_14{	border-style:none;	z-index:2;	position: absolute;	left:154px;	top:614px;	width:25px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_15{	border-style:none;	z-index:2;	position: absolute;	left:109px;	top:706px;	width:25px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_16{	border-style:none;	z-index:2;	position: absolute;	left:200px;	top:553px;	width:26px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_17{	border-style:none;	z-index:2;	position: absolute;	left:324px;	top:1071px;	width:28px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form4_18{	border-style:none;	z-index:2;	position: absolute;	left:216px;	top:402px;	width:28px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}

</style>
<style id="fonts4" type="text/css" >

@font-face {
	font-family: JBCOAH-AdvTA424;
	src: url("4/fonts/JBCOAH-AdvTA42.woff") format("woff");
}

@font-face {
	font-family: JBCNGG-AdvP4C4E744;
	src: url("4/fonts/JBCNGG-AdvP4C4E74.woff") format("woff");
}

@font-face {
	font-family: JBCNFF-AdvOT46dcae814;
	src: url("4/fonts/JBCNFF-AdvOT46dcae81.woff") format("woff");
}

@font-face {
	font-family: JBCNGK-AdvPi14;
	src: url("4/fonts/JBCNGK-AdvPi1.woff") format("woff");
}

@font-face {
	font-family: JBCNGI-AdvOT3b30f6db-B4;
	src: url("4/fonts/JBCNGI-AdvOT3b30f6db-B.woff") format("woff");
}

@font-face {
	font-family: JBCNGH-AdvOT65f8a23b-I4;
	src: url("4/fonts/JBCNGH-AdvOT65f8a23b-I.woff") format("woff");
}

@font-face {
	font-family: JBCPDD-AdvOT7d2ebc014;
	src: url("4/fonts/JBCPDD-AdvOT7d2ebc01.woff") format("woff");
}

</style>
<div id="t1_4" class="t s1_4">patient during follow-up were 17.9 g dl</div>
<div id="t2_4" class="t v1_4 s2_4">±</div>
<div id="t3_4" class="t v1_4 s3_4">1</div>
<div id="t4_4" class="t s1_4">and 52.3%, respectively,</div>
<div id="t5_4" class="t s1_4">and no men required phlebotomy for erythrocytosis treatment.</div>
<div id="t6_4" class="t s1_4">Improvement in hypogonadal symptoms was assessed through</div>
<div id="t7_4" class="t s1_4">direct patient questioning and subjective improvements in</div>
<div id="t8_4" class="t s1_4">energy, libido and erections were each reported by 85%, 85%</div>
<div id="t9_4" class="t s1_4">and 54% of men, respectively.</div>
<div id="ta_4" class="t s4_4">DISCUSSION</div>
<div id="tb_4" class="t s1_4">The use of TRT in the setting of CaP remains controversial, in large</div>
<div id="tc_4" class="t s1_4">part owing to the androgen responsiveness of CaP and the</div>
<div id="td_4" class="t s1_4">concern that TRT will stimulate the growth of latent CaP cells.</div>
<div id="te_4" class="t s1_4">However, mounting evidence supports the safety of TRT in the</div>
<div id="tf_4" class="t s1_4">setting of CaP, though data from randomized controlled trials are</div>
<div id="tg_4" class="t s1_4">currently not available to corroborate these Fndings. This study</div>
<div id="th_4" class="t s1_4">assesses the effects of TRT in hypogonadal men having under-</div>
<div id="ti_4" class="t s1_4">gone radiation treatment for CaP, and our results suggest that the</div>
<div id="tj_4" class="t s1_4">use of TRT in men with a history of CaP does not increase the risk</div>
<div id="tk_4" class="t s1_4">of CaP recurrence or progression for up to 5.5 years after TRT</div>
<div id="tl_4" class="t s1_4">initiation. These results are consistent with the three prior</div>
<div id="tm_4" class="t s1_4">uncontrolled studies assessing the effects of TRT in a total of 43</div>
<div id="tn_4" class="t s1_4">men after radiation therapy,</div>
<div id="to_4" class="t v1_4 s3_4">12–14</div>
<div id="tp_4" class="t s1_4">as well as the three prior studies</div>
<div id="tq_4" class="t s1_4">of TRT in a total of 74 men after RP.</div>
<div id="tr_4" class="t v1_4 s3_4">9–11</div>
<div id="ts_4" class="t s1_4">RP and radiation therapy, even in the absence of ADT, have</div>
<div id="tt_4" class="t s1_4">been associated with changes in serum T levels over time, though</div>
<div id="tu_4" class="t s1_4">the underlying mechanism is unknown. One study found that men</div>
<div id="tv_4" class="t s1_4">treated with radiation therapy were more likely to become</div>
<div id="tw_4" class="t s1_4">hypogonadal than men who underwent RP, with a 27.3% lower T</div>
<div id="tx_4" class="t s1_4">and 31.6% lower ±T in the radiation therapy group.</div>
<div id="ty_4" class="t v1_4 s3_4">20</div>
<div id="tz_4" class="t s1_4">Two</div>
<div id="t10_4" class="t s1_4">additional studies reported T levels that did not recover to</div>
<div id="t11_4" class="t s1_4">pretreatment levels in 40% of men after EBRT, with median</div>
<div id="t12_4" class="t s1_4">decreases in T of 17–19%.</div>
<div id="t13_4" class="t v1_4 s3_4">21,22</div>
<div id="t14_4" class="t s1_4">The increased risk of hypogonadism</div>
<div id="t15_4" class="t s1_4">in the setting of radiation therapy is linked to radiation scatter</div>
<div id="t16_4" class="t s1_4">during treatment and resulting testicular damage.</div>
<div id="t17_4" class="t v1_4 s3_4">23</div>
<div id="t18_4" class="t s1_4">Other studies</div>
<div id="t19_4" class="t s1_4">have reported no signiFcant changes in serum T levels after</div>
<div id="t1a_4" class="t s1_4">radiation therapy,</div>
<div id="t1b_4" class="t v1_4 s3_4">24,25</div>
<div id="t1c_4" class="t s1_4">and several studies have reported drops in T</div>
<div id="t1d_4" class="t s1_4">levels after radiation therapy, with subsequent normalization to</div>
<div id="t1e_4" class="t s1_4">pretreatment levels.</div>
<div id="t1f_4" class="t v1_4 s3_4">26</div>
<div id="t1g_4" class="t s1_4">In the setting of CaP treated with RP, one</div>
<div id="t1h_4" class="t s1_4">study reported increased T levels, though the mechanism behind</div>
<div id="t1i_4" class="t s1_4">this rise is unclear,</div>
<div id="t1j_4" class="t v1_4 s3_4">27</div>
<div id="t1k_4" class="t s1_4">and other studies have reported no changes</div>
<div id="t1l_4" class="t s1_4">in serum T levels after prostatectomy or prostatic adenoma</div>
<div id="t1m_4" class="t s1_4">resection.</div>
<div id="t1n_4" class="t v1_4 s3_4">28,29</div>
<div id="t1o_4" class="t s1_4">Given the variable effects of CaP treatment on</div>
<div id="t1p_4" class="t s1_4">serum T levels, particularly the decline seen in most studies of</div>
<div id="t1q_4" class="t s1_4">men treated with radiation, evaluation for hypogonadism in this</div>
<div id="t1r_4" class="t s1_4">cohort is clearly important.</div>
<div id="t1s_4" class="t s1_4">All 13 men in our cohort received at least 2 months of TRT, with</div>
<div id="t1t_4" class="t s1_4">a median follow-up of 2.5 years after TRT initiation and a</div>
<div id="t1u_4" class="t s1_4">maximum follow-up of approximately 5.5 years. It is important to</div>
<div id="t1v_4" class="t s1_4">note that several patients were treated with subcutaneous</div>
<div id="t1w_4" class="t s1_4">T pellets at some point during therapy and hormone levels were</div>
<div id="t1x_4" class="t s1_4">at times drawn several months after pellet insertion towards the</div>
<div id="t1y_4" class="t s1_4">end of the efFcacy period.</div>
<div id="t1z_4" class="t v1_4 s3_4">30</div>
<div id="t20_4" class="t s1_4">Thus, peak serum T levels may have</div>
<div id="t21_4" class="t s1_4">been missed in several patients at several time points. Neverthe-</div>
<div id="t22_4" class="t s1_4">less, we observed a signiFcant increase in mean T levels during</div>
<div id="t23_4" class="t s1_4">follow-up. ±urthermore, we observed a signiFcant rise in SHBG</div>
<div id="t24_4" class="t s1_4">levels in our cohort, but only at 18–24 months of TRT. While</div>
<div id="t25_4" class="t s1_4">this may be consistent with an increase in serum T, it may also</div>
<div id="t26_4" class="t s1_4">be a statistical artifact considering the time period required</div>
<div id="t27_4" class="t s1_4">for a signiFcant increase. Notably, no signiFcant change in serum E</div>
<div id="t28_4" class="t s1_4">levels was observed, suggesting a low rate of T aromatization</div>
<div id="t29_4" class="t s1_4">within our cohort.</div>
<div id="t2a_4" class="t s1_4">While on TRT, no men in our cohort were found to have</div>
<div id="t2b_4" class="t s1_4">recurrence or progression of their cancer. In contrast, the rate of</div>
<div id="t2c_4" class="t s1_4">biochemical and/or clinical recurrence in the setting of CaP</div>
<div id="t2d_4" class="t s1_4">treated with radiation therapy without TRT is 13–53% and varies</div>
<div id="t2e_4" class="t s1_4">according to the deFnition of recurrence used.</div>
<div id="t2f_4" class="t v1_4 s3_4">31–34</div>
<div id="t2g_4" class="t s1_4">Although one</div>
<div id="t2h_4" class="t s1_4">patient in our cohort had a suspected biochemical recurrence,</div>
<div id="t2i_4" class="t s1_4">subsequent workup demonstrated no evidence of disease.</div>
<div id="t2j_4" class="t s1_4">Notably, this same patient had a baseline T of 40 ng dl</div>
<div id="t2k_4" class="t v1_4 s2_4">±</div>
<div id="t2l_4" class="t v1_4 s3_4">1</div>
<div id="t2m_4" class="t s1_4">after</div>
<div id="t2n_4" class="t s1_4">ADT. This patient’s baseline PSA was 0.009 ng ml</div>
<div id="t2o_4" class="t v1_4 s2_4">±</div>
<div id="t2p_4" class="t v1_4 s3_4">1</div>
<div id="t2q_4" class="t s1_4">and rose to a</div>
<div id="t2r_4" class="t s1_4">high of 1.82 ng ml</div>
<div id="t2s_4" class="t v1_4 s2_4">±</div>
<div id="t2t_4" class="t v1_4 s3_4">1</div>
<div id="t2u_4" class="t s1_4">during TRT, prompting evaluation for CaP</div>
<div id="t2v_4" class="t s1_4">recurrence. However, the observed rise in this patient’s PSA in the</div>
<div id="t2w_4" class="t s1_4">setting of an abnormally low T is consistent with the Prostate</div>
<div id="t2x_4" class="t s1_4">Saturation Theory, which posits that prostatic androgen receptors</div>
<div id="t2y_4" class="t s1_4">may saturate at a serum T level in the castrate range, and that</div>
<div id="t2z_4" class="t s1_4">serum PSA is more likely to rise in the setting of lower serum</div>
<div id="t30_4" class="t s1_4">T levels.</div>
<div id="t31_4" class="t v1_4 s3_4">35</div>
<div id="t32_4" class="t s1_4">Thus, the above patient’s prostatic androgen receptors</div>
<div id="t33_4" class="t s1_4">may not have been saturated at the time of TRT initiation in the</div>
<div id="t34_4" class="t s1_4">setting of castrate T levels, resulting in an initial rise in PSA.</div>
<div id="t35_4" class="t s1_4">However, once the patient was eugonadal and his prostate</div>
<div id="t36_4" class="t s1_4">androgen receptors were saturated, there was no further increase</div>
<div id="t37_4" class="t s1_4">in his PSA.</div>
<div id="t38_4" class="t s1_4">Though numerous deFnitions of biochemical recurrence exist</div>
<div id="t39_4" class="t s1_4">for men with CaP treated with radiation therapy, the three with</div>
<div id="t3a_4" class="t s1_4">the highest sensitivities and speciFcities after EBRT are: (1) PSA</div>
<div id="t3b_4" class="t s1_4">greater than absolute nadir plus 2 ng ml</div>
<div id="t3c_4" class="t v1_4 s2_4">±</div>
<div id="t3d_4" class="t v1_4 s3_4">1</div>
<div id="t3e_4" class="t s1_4">; (2) PSA greater than</div>
<div id="t3f_4" class="t s1_4">current nadir plus 3 ng ml</div>
<div id="t3g_4" class="t v1_4 s2_4">±</div>
<div id="t3h_4" class="t v1_4 s3_4">1</div>
<div id="t3i_4" class="t s1_4">; and (3) two consecutive PSA</div>
<div id="t3j_4" class="t s1_4">increases of</div>
<div id="t3k_4" class="t s5_4">4</div>
<div id="t3l_4" class="t s1_4">0.5 ng ml</div>
<div id="t3m_4" class="t v1_4 s2_4">±</div>
<div id="t3n_4" class="t v1_4 s3_4">1</div>
<div id="t3o_4" class="t s1_4">.</div>
<div id="t3p_4" class="t v1_4 s3_4">36</div>
<div id="t3q_4" class="t s1_4">Even though the absolute nadirs</div>
<div id="t3r_4" class="t s1_4">for most men in our cohort were unavailable, the maximum PSA</div>
<div id="t3s_4" class="t s1_4">after TRT initiation for men treated with EBRT was 1.75 ng ml</div>
<div id="t3t_4" class="t v1_4 s2_4">±</div>
<div id="t3u_4" class="t v1_4 s3_4">1</div>
<div id="t3v_4" class="t s1_4">and no patients experienced two consecutive increases of</div>
<div id="t3w_4" class="t s5_4">4</div>
<div id="t3x_4" class="t s1_4">0.5 ng ml</div>
<div id="t3y_4" class="t v1_4 s2_4">±</div>
<div id="t3z_4" class="t v1_4 s3_4">1</div>
<div id="t40_4" class="t s1_4">, precluding biochemical recurrences according to</div>
<div id="t41_4" class="t s1_4">the above deFnitions and further supporting the safe use of TRT in</div>
<div id="t42_4" class="t s1_4">this cohort of men.</div>
<div id="t43_4" class="t s1_4">±our patients received ADT in addition to radiation therapy, the</div>
<div id="t44_4" class="t s1_4">combination of which has been shown to improve overall survival</div>
<div id="t45_4" class="t s1_4">compared with radiation therapy alone.</div>
<div id="t46_4" class="t v1_4 s3_4">37</div>
<div id="t47_4" class="t s1_4">Given the intermediate-</div>
<div id="t48_4" class="t s1_4">to high-risk nature of cancer in these four men, and in the absence</div>
<div id="t49_4" class="t s1_4">of conFrmed biochemical recurrences, our data support the</div>
<div id="t4a_4" class="t s1_4">efFcacious use of TRT without overt clinical consequences, even in</div>
<div id="t4b_4" class="t s1_4">men with more serious CaP with continued close follow-up.</div>
<div id="t4c_4" class="t s1_4">One of the most common side effects of TRT is erythrocytosis,</div>
<div id="t4d_4" class="t s1_4">which may be caused by suppression of hepcidin by exogenous</div>
<div id="t4e_4" class="t s1_4">T.</div>
<div id="t4f_4" class="t v1_4 s3_4">38</div>
<div id="t4g_4" class="t s1_4">Though rates of erythrocytosis vary depending on the</div>
<div id="t4h_4" class="t s1_4">T formulation, transdermal formulations have an approximately</div>
<div id="t4i_4" class="t s1_4">18% rate of associated erythrocytosis</div>
<div id="t4j_4" class="t v1_4 s3_4">39</div>
<div id="t4k_4" class="t s1_4">and injectable formu-</div>
<div id="t4l_4" class="t s1_4">lations up to 40%. Data are less readily available for rates of</div>
<div id="t4m_4" class="t s1_4">erythrocytosis after treatment with subcutaneous T pellets,</div>
<div id="t4n_4" class="t s1_4">although a recent prospective study of 30 subjects treated with</div>
<div id="t4o_4" class="t s1_4">T pellets resulted in no signiFcant increases in Hct over 6</div>
<div id="t4p_4" class="t s1_4">months.</div>
<div id="t4q_4" class="t v1_4 s3_4">40</div>
<div id="t4r_4" class="t s1_4">Our results overall corroborate the published Fndings,</div>
<div id="t4s_4" class="t s1_4">as no patients developed erythrocytosis over the course of 5.5</div>
<div id="t4t_4" class="t s1_4">years of follow-up. We acknowledge that the small size of our</div>
<div id="t4u_4" class="t s1_4">cohort, as well as limited data, preclude a true assessment of the</div>
<div id="t4v_4" class="t s1_4">effects of TRT on Hgb and Hct parameters.</div>
<div id="t4w_4" class="t s1_4">Our study is limited by several factors. ±irst, as indicated above,</div>
<div id="t4x_4" class="t s1_4">our study was small, comprising only 13 men, and without a</div>
<div id="t4y_4" class="t s1_4">control group. Thus, while several individuals were found to have</div>
<div id="t4z_4" class="t s1_4">rising PSA without recurrence of their CaP, extrapolation to a</div>
<div id="t50_4" class="t s1_4">population level based on such a small cohort is not possible.</div>
<div id="t51_4" class="t s1_4">Second, the retrospective nature of the study resulted in limited</div>
<div id="t52_4" class="t s1_4">data, speciFcally with respect to baseline Hgb and Hct values as</div>
<div id="t53_4" class="t s1_4">well as T levels for men treated with T pellets. Third, the median</div>
<div id="t54_4" class="t s1_4">follow-up of 2.5 years after TRT initiation may be of insufFcient</div>
<div id="t55_4" class="t s1_4">duration to detect biochemical recurrence, as recurrences can</div>
<div id="t56_4" class="t s1_4">occur much longer than 2 years after therapy.</div>
<div id="t57_4" class="t v1_4 s3_4">41</div>
<div id="t58_4" class="t s1_4">±inally, assess-</div>
<div id="t59_4" class="t s1_4">ment of symptomatic improvement on TRT was limited, as</div>
<div id="t5a_4" class="t s1_4">symptoms were not assessed using a validated questionnaire,</div>
<div id="t5b_4" class="t s1_4">though the recent incorporation of a set of validated online</div>
<div id="t5c_4" class="t s1_4">questionnaires in our clinic will remedy this in future work.</div>
<div id="t5d_4" class="t s1_4">In summary, our results are consistent with published data on</div>
<div id="t5e_4" class="t s1_4">CaP patients who receive TRT after RP, radiation therapy and while</div>
<div id="t5f_4" class="t s1_4">on active surveillance. This study also adds to the body of</div>
<div id="t5g_4" class="t s1_4">evidence challenging the androgen-dependent model of CaP</div>
<div id="t5h_4" class="t s1_4">growth while supporting the Prostate Saturation Theory, and</div>
<div id="t5i_4" class="t s1_4">ultimately supporting the use of TRT to treat hypogonadism</div>
<div id="t5j_4" class="t s6_4">Testosterone replacement after radiation treatment for prostate cancer</div>
<div id="t5k_4" class="t s6_4">AW Pastuszak</div>
<div id="t5l_4" class="t s7_4">et al</div>
<div id="t5m_4" class="t s8_4">27</div>
<div id="t5n_4" class="t s9_4">&amp;</div>
<div id="t5o_4" class="t s6_4">2013 Macmillan Publishers Limited</div>
<div id="t5p_4" class="t s6_4">International Journal of Impotence Research (2013), 24 – 28</div>

<form>
<input type="button"  tabindex="15"  id="form4_1" name="30 0 R"  pdfFieldName="30 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="5"  id="form4_2" name="20 0 R"  pdfFieldName="20 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="3"  id="form4_3" name="18 0 R"  pdfFieldName="18 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="16"  id="form4_4" name="31 0 R"  pdfFieldName="31 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="12"  id="form4_5" name="27 0 R"  pdfFieldName="27 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="7"  id="form4_6" name="22 0 R"  pdfFieldName="22 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="18"  id="form4_7" name="33 0 R"  pdfFieldName="33 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="8"  id="form4_8" name="23 0 R"  pdfFieldName="23 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="10"  id="form4_9" name="25 0 R"  pdfFieldName="25 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="17"  id="form4_10" name="32 0 R"  pdfFieldName="32 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="14"  id="form4_11" name="29 0 R"  pdfFieldName="29 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="13"  id="form4_12" name="28 0 R"  pdfFieldName="28 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="2"  id="form4_13" name="17 0 R"  pdfFieldName="17 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="6"  id="form4_14" name="21 0 R"  pdfFieldName="21 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="9"  id="form4_15" name="24 0 R"  pdfFieldName="24 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="4"  id="form4_16" name="19 0 R"  pdfFieldName="19 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="11"  id="form4_17" name="26 0 R"  pdfFieldName="26 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="1"  id="form4_18" name="16 0 R"  pdfFieldName="16 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />

</form>
<div id="pg4Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg4"><object width="909" height="1212" data="4/4.svg" type="image/svg+xml" id="pdf4" style="width:909px; height:1212px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!--[if lt IE 9]><script type="text/javascript">
var divCount = 206;
for (var i = 1; i < divCount; i++) {
    var div = document.getElementById("t" + i.toString(36) + "_4");
    if (div !== null) {
        div.style.top = (div.offsetTop * 4) + "px";
        div.style.left = (div.offsetLeft * 4) + "px";
        div.style.zoom = "25%";
    }
}
</script><![endif]-->

</div>
